日本 COVID-19 大流行期间小儿哮喘住院人数减少,来自一项全国性调查

IF 4.6 2区 医学 Q2 ALLERGY
Seigo Korematsu, Takao Fujisawa, Naruo Saito, Junichiro Tezuka, Katsushi Miura, Ichiro Kobayashi, Ippei Miyata, Yujiro Kosugi, Yuji Gohda, Yumi Koike, Ami Suda, Akiko Matsuo, Michiyo Sasaki, Yousuke Handa, Michimasa Fujiwara, Atsushi Ono, Shinya Koizumi, Taku Oishi, Takayuki Tanaka, Yusuke Ando, Naohiko Taba, Yuki Tsurinaga, Takeshi Sato, Rei Kanai, Masato Yashiro, Toshiyuki Takagi, Shinya Hida, Masashi Harazaki, Takayuki Hoshina, Seigo Okada, Motoko Yasutomi, Setsuko Nakata, Ayako Muto, Saori Tanabe, Yutaka Ueda, Shunji Hasegawa, Makoto Kameda, Keiko Tanaka-Taya, Tsuguto Fujimoto, Kenji Okada
{"title":"日本 COVID-19 大流行期间小儿哮喘住院人数减少,来自一项全国性调查","authors":"Seigo Korematsu,&nbsp;Takao Fujisawa,&nbsp;Naruo Saito,&nbsp;Junichiro Tezuka,&nbsp;Katsushi Miura,&nbsp;Ichiro Kobayashi,&nbsp;Ippei Miyata,&nbsp;Yujiro Kosugi,&nbsp;Yuji Gohda,&nbsp;Yumi Koike,&nbsp;Ami Suda,&nbsp;Akiko Matsuo,&nbsp;Michiyo Sasaki,&nbsp;Yousuke Handa,&nbsp;Michimasa Fujiwara,&nbsp;Atsushi Ono,&nbsp;Shinya Koizumi,&nbsp;Taku Oishi,&nbsp;Takayuki Tanaka,&nbsp;Yusuke Ando,&nbsp;Naohiko Taba,&nbsp;Yuki Tsurinaga,&nbsp;Takeshi Sato,&nbsp;Rei Kanai,&nbsp;Masato Yashiro,&nbsp;Toshiyuki Takagi,&nbsp;Shinya Hida,&nbsp;Masashi Harazaki,&nbsp;Takayuki Hoshina,&nbsp;Seigo Okada,&nbsp;Motoko Yasutomi,&nbsp;Setsuko Nakata,&nbsp;Ayako Muto,&nbsp;Saori Tanabe,&nbsp;Yutaka Ueda,&nbsp;Shunji Hasegawa,&nbsp;Makoto Kameda,&nbsp;Keiko Tanaka-Taya,&nbsp;Tsuguto Fujimoto,&nbsp;Kenji Okada","doi":"10.1002/clt2.12330","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Acute asthma exacerbation in children is often caused by respiratory infections. In this study, a coordinated national surveillance system for acute asthma hospitalizations and causative respiratory infections was established. We herein report recent trends in pediatric acute asthma hospitalizations since the COVID-19 pandemic in Japan.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Thirty-three sentinel hospitals in Japan registered all of their hospitalized pediatric asthma patients and their causal pathogens. The changes in acute asthma hospitalization in children before and after the onset of the COVID-19 pandemic and whether or not COVID-19 caused acute asthma exacerbation were investigated.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>From fiscal years 2010–2019, the median number of acute asthma hospitalizations per year was 3524 (2462–4570), but in fiscal years 2020, 2021, and 2022, the numbers were 820, 1,001, and 1,026, respectively (the fiscal year in Japan is April to March). This decrease was observed in all age groups with the exception of the 3- to 6-year group. SARS-CoV-2 was evaluated in 2094 patients from fiscal years 2020–2022, but the first positive case was not detected until February 2022. Since then, only 36 of them have been identified with SARS-CoV-2, none of which required mechanical ventilation. Influenza, RS virus, and human metapneumovirus infections also decreased in FY 2020. In contrast, 24% of patients had not been receiving long-term control medications before admission despite the severity of bronchial asthma.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>SARS-CoV-2 was hardly detected in children with acute asthma hospitalization during the COVID-19 pandemic. This result indicated that SARS-CoV-2 did not induce acute asthma exacerbation in children. Rather, infection control measures implemented against the pandemic may have consequently reduced other respiratory virus infections and thus acute asthma hospitalizations during this period. However, the fact that many hospitalized patients have not been receiving appropriate long-term control medications is a major problem that should be addressed.</p>\n </section>\n </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12330","citationCount":"0","resultStr":"{\"title\":\"Suppressed pediatric asthma hospitalizations during the COVID-19 pandemic in Japan, from a national survey\",\"authors\":\"Seigo Korematsu,&nbsp;Takao Fujisawa,&nbsp;Naruo Saito,&nbsp;Junichiro Tezuka,&nbsp;Katsushi Miura,&nbsp;Ichiro Kobayashi,&nbsp;Ippei Miyata,&nbsp;Yujiro Kosugi,&nbsp;Yuji Gohda,&nbsp;Yumi Koike,&nbsp;Ami Suda,&nbsp;Akiko Matsuo,&nbsp;Michiyo Sasaki,&nbsp;Yousuke Handa,&nbsp;Michimasa Fujiwara,&nbsp;Atsushi Ono,&nbsp;Shinya Koizumi,&nbsp;Taku Oishi,&nbsp;Takayuki Tanaka,&nbsp;Yusuke Ando,&nbsp;Naohiko Taba,&nbsp;Yuki Tsurinaga,&nbsp;Takeshi Sato,&nbsp;Rei Kanai,&nbsp;Masato Yashiro,&nbsp;Toshiyuki Takagi,&nbsp;Shinya Hida,&nbsp;Masashi Harazaki,&nbsp;Takayuki Hoshina,&nbsp;Seigo Okada,&nbsp;Motoko Yasutomi,&nbsp;Setsuko Nakata,&nbsp;Ayako Muto,&nbsp;Saori Tanabe,&nbsp;Yutaka Ueda,&nbsp;Shunji Hasegawa,&nbsp;Makoto Kameda,&nbsp;Keiko Tanaka-Taya,&nbsp;Tsuguto Fujimoto,&nbsp;Kenji Okada\",\"doi\":\"10.1002/clt2.12330\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Acute asthma exacerbation in children is often caused by respiratory infections. In this study, a coordinated national surveillance system for acute asthma hospitalizations and causative respiratory infections was established. We herein report recent trends in pediatric acute asthma hospitalizations since the COVID-19 pandemic in Japan.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Thirty-three sentinel hospitals in Japan registered all of their hospitalized pediatric asthma patients and their causal pathogens. The changes in acute asthma hospitalization in children before and after the onset of the COVID-19 pandemic and whether or not COVID-19 caused acute asthma exacerbation were investigated.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>From fiscal years 2010–2019, the median number of acute asthma hospitalizations per year was 3524 (2462–4570), but in fiscal years 2020, 2021, and 2022, the numbers were 820, 1,001, and 1,026, respectively (the fiscal year in Japan is April to March). This decrease was observed in all age groups with the exception of the 3- to 6-year group. SARS-CoV-2 was evaluated in 2094 patients from fiscal years 2020–2022, but the first positive case was not detected until February 2022. Since then, only 36 of them have been identified with SARS-CoV-2, none of which required mechanical ventilation. Influenza, RS virus, and human metapneumovirus infections also decreased in FY 2020. In contrast, 24% of patients had not been receiving long-term control medications before admission despite the severity of bronchial asthma.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>SARS-CoV-2 was hardly detected in children with acute asthma hospitalization during the COVID-19 pandemic. This result indicated that SARS-CoV-2 did not induce acute asthma exacerbation in children. Rather, infection control measures implemented against the pandemic may have consequently reduced other respiratory virus infections and thus acute asthma hospitalizations during this period. However, the fact that many hospitalized patients have not been receiving appropriate long-term control medications is a major problem that should be addressed.</p>\\n </section>\\n </div>\",\"PeriodicalId\":10334,\"journal\":{\"name\":\"Clinical and Translational Allergy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-01-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12330\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Translational Allergy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/clt2.12330\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Allergy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/clt2.12330","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

摘要

背景 儿童哮喘急性加重通常是由呼吸道感染引起的。本研究建立了一个协调的全国哮喘急性期住院病例和致病呼吸道感染监测系统。我们在此报告自 COVID-19 在日本大流行以来儿童急性哮喘住院治疗的最新趋势。 方法 日本的 33 家哨点医院登记了所有住院的小儿哮喘患者及其致病病原体。调查了COVID-19大流行前后儿童急性哮喘住院病例的变化,以及COVID-19是否导致急性哮喘加重。 结果 2010-2019财年,每年急性哮喘住院人数的中位数为3524人(2462-4570人),但2020、2021和2022财年的人数分别为820人、1001人和1026人(日本的财年为4月至次年3月)。除 3-6 岁年龄组外,所有年龄组的人数都出现了下降。对 2020-2022 财年的 2094 名患者进行了 SARS-CoV-2 评估,但直到 2022 年 2 月才发现首例阳性病例。从那时起,只有 36 名患者被确认感染了 SARS-CoV-2,其中无一人需要机械通气。流感、RS 病毒和人类偏肺病毒感染在 2020 财政年度也有所减少。相比之下,尽管支气管哮喘的病情严重,但仍有 24% 的患者在入院前未接受长期控制药物治疗。 结论 在 COVID-19 大流行期间,急性哮喘住院患儿中几乎检测不到 SARS-CoV-2。这一结果表明,SARS-CoV-2 并未诱发儿童哮喘急性加重。相反,针对大流行采取的感染控制措施可能因此减少了其他呼吸道病毒感染,从而减少了这一时期的急性哮喘住院病例。然而,许多住院病人并未接受适当的长期控制药物治疗,这是一个亟待解决的重大问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Suppressed pediatric asthma hospitalizations during the COVID-19 pandemic in Japan, from a national survey

Suppressed pediatric asthma hospitalizations during the COVID-19 pandemic in Japan, from a national survey

Background

Acute asthma exacerbation in children is often caused by respiratory infections. In this study, a coordinated national surveillance system for acute asthma hospitalizations and causative respiratory infections was established. We herein report recent trends in pediatric acute asthma hospitalizations since the COVID-19 pandemic in Japan.

Methods

Thirty-three sentinel hospitals in Japan registered all of their hospitalized pediatric asthma patients and their causal pathogens. The changes in acute asthma hospitalization in children before and after the onset of the COVID-19 pandemic and whether or not COVID-19 caused acute asthma exacerbation were investigated.

Results

From fiscal years 2010–2019, the median number of acute asthma hospitalizations per year was 3524 (2462–4570), but in fiscal years 2020, 2021, and 2022, the numbers were 820, 1,001, and 1,026, respectively (the fiscal year in Japan is April to March). This decrease was observed in all age groups with the exception of the 3- to 6-year group. SARS-CoV-2 was evaluated in 2094 patients from fiscal years 2020–2022, but the first positive case was not detected until February 2022. Since then, only 36 of them have been identified with SARS-CoV-2, none of which required mechanical ventilation. Influenza, RS virus, and human metapneumovirus infections also decreased in FY 2020. In contrast, 24% of patients had not been receiving long-term control medications before admission despite the severity of bronchial asthma.

Conclusion

SARS-CoV-2 was hardly detected in children with acute asthma hospitalization during the COVID-19 pandemic. This result indicated that SARS-CoV-2 did not induce acute asthma exacerbation in children. Rather, infection control measures implemented against the pandemic may have consequently reduced other respiratory virus infections and thus acute asthma hospitalizations during this period. However, the fact that many hospitalized patients have not been receiving appropriate long-term control medications is a major problem that should be addressed.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical and Translational Allergy
Clinical and Translational Allergy Immunology and Microbiology-Immunology
CiteScore
7.50
自引率
4.50%
发文量
117
审稿时长
12 weeks
期刊介绍: Clinical and Translational Allergy, one of several journals in the portfolio of the European Academy of Allergy and Clinical Immunology, provides a platform for the dissemination of allergy research and reviews, as well as EAACI position papers, task force reports and guidelines, amongst an international scientific audience. Clinical and Translational Allergy accepts clinical and translational research in the following areas and other related topics: asthma, rhinitis, rhinosinusitis, drug hypersensitivity, allergic conjunctivitis, allergic skin diseases, atopic eczema, urticaria, angioedema, venom hypersensitivity, anaphylaxis, food allergy, immunotherapy, immune modulators and biologics, animal models of allergic disease, immune mechanisms, or any other topic related to allergic disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信